These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1421823)

  • 1. The manufacturing process of recombinant factor VIII, recombinate.
    Gomperts E; Lundblad R; Adamson R
    Transfus Med Rev; 1992 Oct; 6(4):247-51. PubMed ID: 1421823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinate: viral safety and final product manufacturing testing and specifications.
    Lawrence J
    Ann Hematol; 1994; 68 Suppl 3():S21-4. PubMed ID: 8180253
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII.
    Mannully ST; L N R; Pulicherla KK
    Int J Biol Macromol; 2018 Nov; 119():496-504. PubMed ID: 30063930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new albumin-free recombinant factor VIII concentrates for treatment of hemophilia: do they represent an actual incremental improvement?
    Josephson CD; Abshire T
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):441-6. PubMed ID: 16163220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.
    Besman MJ; Shiba D
    Pharm Res; 1997 Aug; 14(8):1092-8. PubMed ID: 9279894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII.
    Adamson R
    Ann Hematol; 1994; 68 Suppl 3():S9-14. PubMed ID: 8180266
    [No Abstract]   [Full Text] [Related]  

  • 7. Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system.
    Orlova NA; Kovnir SV; Gabibov AG; Vorobiev II
    BMC Biotechnol; 2017 Mar; 17(1):33. PubMed ID: 28340620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced production of recombinant B-domain deleted factor VIII from Chinese hamster ovary cells by propionic and butyric acids.
    Chun BH; Park SY; Chung N; Bang WG
    Biotechnol Lett; 2003 Feb; 25(4):315-9. PubMed ID: 12882544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BAY 81-8973, a full-length recombinant factor VIII: Human heat shock protein 70 improves the manufacturing process without affecting clinical safety.
    Maas Enriquez M; Thrift J; Garger S; Katterle Y
    Protein Expr Purif; 2016 Nov; 127():111-115. PubMed ID: 27436242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baby hamster kidney cell-derived recombinant factor VIII: a quarter century of learning and clinical experience.
    Afonja O; Kozak R; Petraro P; Michaels LA; Mathew P; Lemm G; Kessler C
    Expert Rev Hematol; 2016 Dec; 9(12):1151-1164. PubMed ID: 27841041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The manufacturing of the recombinant factor VIII, Kogenate.
    Boedeker BG
    Transfus Med Rev; 1992 Oct; 6(4):256-60. PubMed ID: 1421825
    [No Abstract]   [Full Text] [Related]  

  • 13. Cell culture and purification process--purity and safety testing.
    Koplove HM
    Ann Hematol; 1994; 68 Suppl 3(Suppl 3):S15-20. PubMed ID: 8180252
    [No Abstract]   [Full Text] [Related]  

  • 14. Production of recombinant human factor VIII in different cell lines and the effect of human XBP1 co-expression.
    Campos-da-Paz M; Costa CS; Quilici LS; de Carmo Simões I; Kyaw CM; Maranhão AQ; Brigido MM
    Mol Biotechnol; 2008 Jun; 39(2):155-8. PubMed ID: 18327549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotechnology and the plasma fractionation industry--the impact of advances in the production of coagulation factor VIII.
    Farrugia A
    Australas Biotechnol; 1993; 3(1):16-20. PubMed ID: 7763537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative approach for improved rFVIII concentrate.
    Morfini M
    Eur J Haematol; 2014 Nov; 93(5):361-8. PubMed ID: 24766411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral safety of B-domain deleted recombinant factor VIII.
    Charlebois TS; O'connell BD; Adamson SR; Brink-Nilsson H; Jernberg M; Eriksson B; Kelley BD
    Semin Hematol; 2001 Apr; 38(2 Suppl 4):32-9. PubMed ID: 11449333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.
    Ahmadian H; Hansen EB; Faber JH; Sejergaard L; Karlsson J; Bolt G; Hansen JJ; Thim L
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):568-75. PubMed ID: 26761578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study.
    Ewenstein BM; Gomperts ED; Pearson S; O'Banion ME
    Haemophilia; 2004 Sep; 10(5):491-8. PubMed ID: 15357776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production processes of licensed recombinant factor VIII preparations.
    Boedeker BG
    Semin Thromb Hemost; 2001 Aug; 27(4):385-94. PubMed ID: 11547361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.